Mealey's (March 16, 2017, 3:47 PM EDT) -- WASHINGTON, D.C. — Amgen Inc. filed its opening and response brief on March 10 in its high-stakes suit with Sandoz Inc., arguing that the Federal Circuit U.S. Court of Appeals did not err by requiring biosimilar makers to get approval before supplying 180-day notice of sales to rivals because permitting notice before approval is consistent with “early resolution of patent disputes” (Sandoz Inc. v. Amgen Inc. and Amgen Manufacturing Ltd., No. 15-1039, U.S. Sup.)....